Neuromuscular disease: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 63: Line 63:
*[[Muscle]]
*[[Muscle]]
*[[ICD-10_Chapter_XIII:_Diseases_of_the_musculoskeletal_system_and_connective_tissue]]
*[[ICD-10_Chapter_XIII:_Diseases_of_the_musculoskeletal_system_and_connective_tissue]]
*[[Centronuclear myopathy (including myotubular myopathy)|Centronuclear myopathy]]
*[[Centronuclear myopathy (including myotubular myopathy)|Myotubular myopathy]]


==References==
==References==
Line 68: Line 70:


[[Category:Muscular system]]
[[Category:Muscular system]]
*[[Centronuclear myopathy (including myotubular myopathy)|Centronuclear myopathy]]
*[[Centronuclear myopathy (including myotubular myopathy)|Myotubular myopathy]]


[[nl:Spierziekte]]
[[nl:Spierziekte]]
{{WikiDoc Sources}}
{{WikiDoc Sources}}

Revision as of 13:14, 5 October 2012

Neuromuscular disease
MeSH D009468

Overview

Neuromuscular disease is a very broad term that encompasses many diseases and ailments that either directly (via intrinsic muscle pathology) or indirectly (animal muscle in general.

Neuromuscular diseases are those that affect the muscles and/or their nervous control. In general, problems with nervous control can cause spasticity or paralysis, depending on the location and nature of the problem. A large proportion of neurological disorders leads to problems with movement, ranging from cerebrovascular accident (stroke) and Parkinson's disease to Creutzfeldt-Jakob disease.

Causes

Symptoms

Symptoms of muscle disease may include

Laboratory Findings

Diagnostic procedures that may reveal muscular disorders include testing creatine kinase levels in the blood and electromyography (measuring electrical activity in muscles).

ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (DO NOT EDIT) [1]

Recommendations for Neuromuscular Disorders

Class I
"1. Patients with neuromuscular disorders who have ventricular arrhythmias should generally be treated in the same manner as patients without neuromuscular disorders. (Level of Evidence: A). "

Related Chapters

References

  1. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M; et al. (2006). "ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society". Circulation. 114 (10): e385–484. doi:10.1161/CIRCULATIONAHA.106.178233. PMID 16935995.

nl:Spierziekte Template:WikiDoc Sources